Piper Sandler analyst Christopher Raymond maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of $66.00. The company’s shares closed yesterday at $48.14.
According to TipRanks, Raymond is a 4-star analyst with an average return of 6.0% and a 52.11% success rate. Raymond covers the Healthcare sector, focusing on stocks such as AbbVie, Regeneron, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Biohaven Ltd. is a Strong Buy with an average price target of $58.00, which is a 20.48% upside from current levels. In a report released today, TD Cowen also assigned a Buy rating to the stock with a $55.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $50.68 and a one-year low of $12.35. Currently, Biohaven Ltd. has an average volume of 1.05M.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BHVN in relation to earlier this year. Most recently, in December 2023, Irina Antonijevic, a Director at BHVN sold 11,000.00 shares for a total of $459,580.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Ltd. (BHVN) Company Description:
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Read More on BHVN:
- Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
- JPMorgan biotech analysts to hold an analyst/industry conference call
- Biohaven price target raised to $56 from $32 at JPMorgan
- UPS upgraded, Nike downgraded: Wall Street’s top analyst calls
- RBC Capital starts Biohaven at Outperform, sees BHV-7000 with over $1B potential
